https://newsroom.ionis-group.com/
Newsroom IONIS Education Group
Sep 15, 2025 - Que vous soyez journaliste ou simplement à la recherche d'informations sur le Groupe IONIS et ses écoles, vous êtes à la bonne place.
newsroomioniseducationgroup
https://www.financialcontent.com/article/bizwire-2026-1-12-ionis-well-positioned-for-continued-momentum-and-substantial-value-creation-in-2026-with-two-new-independent-launches-and-several-pivotal-data-readouts
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2025 achievements and provided additional updates on key milestones...
https://finviz.com/quote?t=IONS&ta=1&p=m&ty=lf
IONS - Ionis Pharmaceuticals Inc Latest SEC Filings
IONS - Ionis Pharmaceuticals Inc - Stock screener for investors and traders, financial visualizations.
ionis pharmaceuticals incionslatestsecfilings
https://www.benzinga.com/news/earnings/23/05/32163484/ionis-pharmaceuticalss-earnings-outlook
Ionis Pharmaceuticals's Earnings Outlook - Ionis Pharmaceuticals (NASDAQ:IONS) - Benzinga
ionis pharmaceuticalsearningsoutlooknasdaqions
https://www.prnewswire.com/news-releases/ionis-enters-agreement-with-roche-for-two-novel-rna-targeted-programs-for-alzheimers-disease-and-huntingtons-disease-301939627.html
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and...
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered an agreement with Roche for two undisclosed early-stage...
https://www.lawinsider.com/contracts/cuqLyeKXD1b
LOAN AGREEMENT by Ionis Pharmaceuticals Inc | Law Insider
LOAN AGREEMENT filed by Ionis Pharmaceuticals Inc on July 21st, 2017
ionis pharmaceuticals incloan agreementlawinsider
https://www.prnewswire.com/news-releases/ionis-announces-fda-acceptance-of-new-drug-application-for-eplontersen-for-the-treatment-of-hereditary-transthyretin-mediated-amyloid-polyneuropathy-attrv-pn-301764027.html
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of...
/PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug...
new drug application
https://www.prnewswire.com/news-releases/ionis-partner-to-evaluate-tominersen-for-huntingtons-disease-in-new-phase-2-trial-301462286.html
Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that its partner, Roche, is designing a new Phase 2 trial to evaluate tominersen in...
https://www.trivago.com/en-US/oar/ionis-hotel-peratata?search=100-2764410
Ionis Hotel, Peratata, Greece - www.trivago.com
Compare hotel prices and find an amazing price for the Ionis Hotel Hotel in Peratata, Greece. View 23 photos and read 587 reviews. Hotel? trivago!
peratata greeceionishotelwwwtrivago
https://www.macrotrends.net/stocks/charts/IONS/ionis-pharmaceuticals/price-sales
Ionis Pharmaceuticals Price to Sales Ratio 2012-2026 | IONS | MacroTrends
Historical PS ratio values for Ionis Pharmaceuticals (IONS) over the last 10 years. The current P/S ratio for Ionis Pharmaceuticals as of May 12, 2026 is...
price to sales ratioionis pharmaceuticals20122026ions
https://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-present-at-upcoming-investor-conferences-300703774.html
Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company...
ionis pharmaceuticalspresentupcominginvestorconferences
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ions/ionis-pharmaceuticals/news/analysts-just-published-a-bright-new-outlook-for-ionis-pharm
Analysts Just Published A Bright New Outlook For Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) -...
Celebrations may be in order for Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) shareholders, with the analysts delivering...
https://www.financialcontent.com/article/bizwire-2026-2-17-ionis-updates-time-for-fourth-quarter-and-full-year-2025-financial-results-webcast
Ionis updates time for fourth quarter and full year 2025 financial results webcast |...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a change in the start time for its fourth quarter and full year 2025 financial results webcast.
https://www.biospace.com/ionis-to-present-at-upcoming-investor-conference
Ionis to present at upcoming investor conference - BioSpace
Jul 5, 2023 - Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at TD Cowen's 2nd Annual RNA Therapeutics Summit...
investor conferenceionispresentupcoming
https://www.prnewswire.com/news-releases/ionis-and-genuity-science-announce-agreement-designed-to-rapidly-translate-genomic-insights-into-therapeutics-301143671.html
Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into...
/PRNewswire/ -- Genuity Science, a genomics and data insights organization and Ionis Pharmaceuticals (NASDAQ: IONS), the leader in antisense therapeutics,...
https://ffm.bio/aepqxqa
IONIS
ionis
https://ionisai.com/
AI Automation Agency for B2B Growth | Ionis AI
AI automation agency building growth systems for B2B businesses. Cold email, AI agents, dashboards, and SEO audits. Book a free discovery call.
ai automation agencyfor b2bgrowthionis
https://www.mdanderson.org/newsroom/archived-news/md-anderson-and-ioni.h00-159066345.html
ARCHIVED: MD Anderson and Ionis Pharmaceuticals form strategic alliance to advance novel cancer...
Ionis Pharmaceuticals, Inc.,and The University of Texas MD Anderson Cancer Center today announced the formation of a strategic alliance to discover and develop...
https://www.financialcontent.com/article/bizwire-2026-2-19-ionis-to-present-at-upcoming-investor-conferences
Ionis to present at upcoming investor conferences | FinancialContent
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
investor conferencesionispresentupcoming
https://www.financialcontent.com/quote/NQ:IONS/historical
Historical Stock Prices for Ionis Pharmaceuticals, Inc. - Common Stock (Nasdaq:IONS) |...
Daily Stock Prices for Ionis Pharmaceuticals, Inc. - Common Stock (Nasdaq:IONS), Including Open, High, Low, and Close for the past 25 years
ionis pharmaceuticals incstock priceshistoricalcommonnasdaq
https://www.biospace.com/ionis-to-host-2024-virtual-annual-meeting-of-stockholders
Ionis to host 2024 virtual Annual Meeting of Stockholders - BioSpace
May 15, 2024 - Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a general...
to hostannual meetingionis2024virtual
https://www.fiercebiotech.com/research/how-ionis-antisense-drugs-could-work-2-neurodegenerative-diseases
How Ionis' antisense drugs could help combat ALS and dementia | Fierce Biotech
Sep 2, 2020 - Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are two fatal neurodegenerative diseases marked by different clinical signs.
antisense drugs
https://www.financialcontent.com/quote/NQ:IONS/competitors
Competitors for Ionis Pharmaceuticals, Inc. - Common Stock (Nasdaq:IONS) | FinancialContent
ionis pharmaceuticals inccommon stockcompetitorsnasdaqions
https://www.ionis-tbb.de/
Ionis Tauberbischofsheim Tauberbischofsheim
ionistauberbischofsheim
https://www.financialcontent.com/quote/NQ:IONS/faq
Frequently Asked Questions about Ionis Pharmaceuticals, Inc. - Common Stock (Nasdaq:IONS) |...
See our most frequently asked questions about Ionis Pharmaceuticals, Inc. - Common Stock (Nasdaq:IONS)
frequently asked questionsionis pharmaceuticals inccommon stock
https://www.insidermonkey.com/blog/is-ionis-pharmaceuticals-inc-ions-a-promising-biotech-stock-according-to-wall-street-analysts-1492695/
Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts -...
We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Ionis...
https://www.news-medical.net/suppliers/Ionis-Pharmaceuticals-Inc.aspx
Ionis Pharmaceuticals, Inc. : Quotes, Address, Contact
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a...
ionis pharmaceuticals incquotesaddress
https://www.ig.com/au/shares/markets-shares/isis-pharmaceuticals-inc-ISIS-US
Trade Ionis Pharmaceuticals Inc Shares | Live Ionis Pharmaceuticals Inc Share Price | IG Australia...
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases.... [AU]
ionis pharmaceuticals inclive sharetradesharesprice
https://www.benzinga.com/general/biotech/22/01/25182558/ionis-eplontersen-receives-fda-orphan-drug-status-for-misfolded-protein-disorder
Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder - AstraZeneca...
orphan drug status
https://www.ionis.de/
Ionis Gastrobetriebe
ionisgastrobetriebe
https://www.prnewswire.com/news-releases/ionis-partner-biogen-announces-that-results-from-phase-3-valor-study-and-open-label-extension-of-tofersen-showed-clinical-benefit-in-sod1-als-patients-301560770.html
Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of...
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Biogen today announced results from the Phase 3 VALOR study and its open-label extension...
https://www.epo.org/de/boards-of-appeal/decisions/t211361eu1
T 1361/21 (Allelic variants/IONIS PHARMACEUTICALS) vom 07.03.2024
ionis pharmaceuticals136121allelicvariants
https://www.financialcontent.com/quote/NQ:IONS/chart
Stock Chart for Ionis Pharmaceuticals, Inc. - Common Stock (Nasdaq:IONS) | FinancialContent
View a technical stock chart for Ionis Pharmaceuticals, Inc. - Common Stock (Nasdaq:IONS)
ionis pharmaceuticals incstock chartcommonnasdaqions
https://informaconnect.com/tides/speakers/jennifer-franklin/
Jennifer Franklin - Ionis Pharmaceuticals | TIDES USA: Oligonucleotide & Peptide Therapeutics...
jennifer franklinionis pharmaceuticalstidesusaoligonucleotide
https://www.benzinga.com/general/biotech/23/09/34917947/ionis-pharmaceuticals-rare-metabolic-disorder-candidate-poised-to-become-new-standard-treatment-s
Why Ionis Pharmaceuticals (IONS) Stock Is Trading Higher Today - Ionis Pharmaceuticals...
Sep 26, 2023 - Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome...
ionis pharmaceuticalsionsstocktradinghigher
https://www.biospace.com/ionis-announces-positive-detailed-results-from-the-halos-study-of-ion582-in-people-with-angelman-syndrome
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman...
https://www.fiercebiotech.com/biotech/astrazeneca-will-have-wait-little-longer-fruit-35b-ionis-attr-partnership
AstraZeneca will have to wait a little longer for fruit from $3.5B Ionis ATTR partnership | Fierce...
Apr 29, 2022 - AstraZeneca is going to have to wait a little bit longer to see the fruits of its more than $3.5 billion partnership with Ionis Pharmaceuticals.
https://finviz.com/quote?t=IONS&ty=oc&ta=0&p=d
IONS - Ionis Pharmaceuticals Inc Options
IONS - Ionis Pharmaceuticals Inc - Stock screener for investors and traders, financial visualizations.
ionis pharmaceuticals incions
https://ionis.com/
Innovating to Change the Course of Human Health | IONIS
Discover how we are enabling better futures for people living with serious disease through groundbreaking innovations. Learn about our mission here.
to changethe coursehuman healthinnovatingionis
https://www.ionis-hotel.gr/
Ionis Hotel Lefkada - Lefkada hotels - Official Site
Ionis Hotel - Ionis Hotel Lefkada
ionishotellefkadaofficialsite
https://www.biospace.com/biogen-drops-ionis-partnered-assets-in-als-angelman-syndrome-after-early-stage-readouts
Biogen Drops Ionis-Partnered Assets in ALS, Angelman Syndrome After Early-Stage Readouts - BioSpace
Jul 24, 2024 - Disappointed with Phase I/II results for two Ionis-partnered programs, one for amyotrophic lateral sclerosis and another for Angelman syndrome, Biogen has...
https://www.fiercebiotech.com/biotech/novartis-pays-150m-to-license-akcea-ionis-cardiac-disease-drug
Novartis pays $150M to license Akcea-Ionis cardiac disease drug | Fierce Biotech
Feb 25, 2019 - Novartis has taken up its option to license antisense oligonucleotide TQJ230, triggering a $150 million payout that Akcea Therapeutics will share with Ionis...
https://www.ionis-mobile.de/
Ionis.mobile Cocktail-Catering Wertheim
cocktail cateringionismobilewertheim
https://www.oanda.com/eu-lv/trading/shares/us/ionis-pharmaceuticals
Ionis Pharmaceuticals Inc (IONS) Trading | Shares / Shares CFDs | OANDA
Trade Ionis Pharmaceuticals Inc (IONS) shares CFDs with OANDA. View live charts and current market interest for this stock.
ionis pharmaceuticals incionstradingsharescfds
https://www.nasdaq.com/market-activity/stocks/ions
Ionis Pharmaceuticals, Inc. Common Stock (IONS) Stock Price, Quote, News & History | Nasdaq
Discover real-time Ionis Pharmaceuticals, Inc. Common Stock (IONS) stock prices, quotes, historical data, news, and Insights for informed trading and...
ionis pharmaceuticals inccommon stockprice quotenews history
https://www.fiercebiotech.com/biotech/ionis-astrazenecas-polyneuropathy-med-improved-patients-quality-life-phase-3-teeing-battle
Ionis, AstraZeneca crack open phase 3 data of Alnylam rival
Apr 24, 2023 - Ionis and AstraZeneca are enthusiastic about the prospects of eplontersen after presenting new phase 3 data in patients with ATTR polyneuropathy.
phase 3ionisastrazenecacrackopen
https://finviz.com/quote?t=IONS&ta=1&p=d&ty=oc
IONS - Ionis Pharmaceuticals Inc Options
IONS - Ionis Pharmaceuticals Inc - Stock screener for investors and traders, financial visualizations.
ionis pharmaceuticals incions
https://www.financialcontent.com/article/bizwire-2026-2-11-ionis-to-hold-fourth-quarter-and-full-year-2025-financial-results-webcast
Ionis to hold fourth quarter and full year 2025 financial results webcast | FinancialContent
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 25 at 11:30 a.m. Eastern Time to discuss its...
https://www.home.saxo/pl-pl/markets/stocks/ions-xnas
Ionis Pharmaceuticals Inc. akcja | Saxo Bank
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs.
ionis pharmaceuticals incakcjasaxobank
https://www.prnewswire.com/news-releases/ionis-and-royalty-pharma-enter-into-royalty-agreement-for-up-to-1-1-billion-to-further-advance-ionis-genetic-medicines-and-commercial-readiness-301716470.html
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance...
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma has acquired an interest...
https://www.fiercebiotech.com/keyword/ionis-pharmaceuticals
Ionis Pharmaceuticals | Fierce Biotech
ionis pharmaceuticalsfiercebiotech
https://www.finanzen.net/aktien/ionis_pharmaceuticals-aktie
IONIS PHARMACEUTICALS AKTIE | Aktienkurs | US4622221004 | IONS | A2ACMZ | News | finanzen.net
IONIS PHARMACEUTICALS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Ionis Pharmaceuticals Inc | A2ACMZ | IONS | US4622221004
ionis pharmaceuticalsaktieionsnewsfinanzen
https://www.financialcontent.com/article/bizwire-2026-3-9-ionis-announces-changes-to-board-of-directors
Ionis announces changes to Board of Directors | FinancialContent
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced upcoming transitions on its Board of Directors. B. Lynne Parshall, Esq., and Joseph Wender will be...
board of directorsionisannounceschanges
https://www.prnewswire.com/news-releases/ionis-appoints-eugene-schneider-md-as-executive-vice-president-and-chief-clinical-development-officer-301203128.html
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development...
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the appointment of Eugene Schneider, M.D., as executive vice president and chief...
https://menafn.com/1110418835/Metagenomi-To-Present-Preclinical-Data-Supporting-New-Collaboration-Target-Of-APOC3-With-Ionis-Pharmaceuticals-At-Upcoming-Nature-Conference
Metagenomi To Present Preclinical Data Supporting New Collaboration Target Of APOC3 With Ionis...
Metagenomi To Present Preclinical Data Supporting New Collaboration Target Of APOC3 With Ionis Pharmaceuticals At Upcoming Nature Conference. EMERYVILLE,...
https://www.prnewswire.com/news-releases/ionis-to-hold-third-quarter-2024-financial-results-webcast-302283732.html
Ionis to hold third quarter 2024 financial results webcast
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern...
2024 financial resultsthird quarterionisholdwebcast
https://www.marketscreener.com/quote/stock/IONIS-PHARMACEUTICALS-INC-25500637/sector-valuation/
Ionis Pharmaceuticals, Inc.: Sectoral Comparison of Valuation (Other Biotechnology & Medical...
ionis pharmaceuticals incsectoralcomparisonvaluationbiotechnology